Bucillamine

Bucillamine

Systematic (IUPAC) name
2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	65002-17-7
ATC code	M01CC02
PubChem	CID 656604
ChemSpider	570965^Y
UNII	R80LRA5WTF^Y
KEGG	D01809^Y
ChEMBL	CHEMBL80830^Y
Chemical data
Formula	C₇H₁₃N O₃S₂
Mol. mass	223.31302 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)/t4-/m0/s1^Y Key:VUAFHZCUKUDDBC-BYPYZUCNSA-N^Y
Y(what is this?) (verify)

Bucillamine is an antirheumatic agent developed from tiopronin. It is mainly used in Japan and Korea. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. ^[1]

References

^ Amersi, F. (2002). "Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury". Proceedings of the National Academy of Sciences 99: 8915. doi:10.1073/pnas.132026099.

Specific antirheumatic products / DMARDs (M01C)

Quinolines

Oxycinchophen

Gold preparations

Sodium aurothiomalate • Sodium aurothiosulfate • Auranofin • Aurothioglucose • Aurotioprol

Other

Penicillamine #/Bucillamine • Chloroquine #/Hydroxychloroquine • Leflunomide • Sulfasalazine # • antifolate (Methotrexate #) • thiopurine (Azathioprine) #

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

M: JNT

anat(h/c, u, t, l)/phys

noco(arth/defr/back/soft)/cong, sysi/epon, injr

proc, drug(M01C, M4)